JPMorgan Chase & Co. Initiates AnaptysBio, Inc. (NASDAQ:ANAB) At Overweight With Target Price Of $ 115.00

AnaptysBio, Inc. (NASDAQ:ANAB) initiated by JPMorgan Chase & Co. at Overweight rating. The research firm sets target price at $ 115.00.

According to the previous trading day, closing price of ANAB was $ 69.05, representing a 10.37 % increase from the 52 week low of $ 62.56 and a 48.47 % decrease over the 52 week high of $ 134.00.

AnaptysBio, Inc. has a market capital of $ 1.85 billion and is part of the Healthcare sector and Biotechnology industry.